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VASCULAR BIOLOGY
Toll-like receptor 4 in lymphatic endothelial cells contributes to LPS-induced
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The lymphatic vessel is a major conduit
for immune cell transport; however, little
is known about how lymphatic vessels
regulate immune cell trafficking and how
lymphatic vessels themselves respond to
inflammation. Toll-like receptor 4 (TLR4)
plays a central role in lipopolysaccharide
(LPS)–induced inflammation, but the role
of TLR4 in lymphatic endothelial cells
(LECs) is poorly understood. Here, we
found that LECs express high amounts of
TLR4 in the intracellular region, and that
the TLR4 of LECs is the main mediator of
nuclear factor–B (NF-B) activation by
LPS. LPS-TLR4 signaling in LECs re-
sulted in the production of various chemo-
kines for chemotaxis of macrophage. In
addition, TLR4 in LECs actively contrib-
uted to the recruitment of macrophages
to the draining lymphatic vessel. Further-
more, the macrophages that infiltrated
into the lymphatic vessel induced lym-
phangiogenesis by secreting lymphangio-
genic growth factors. These phenomena
were largely attenuated not only in the
mice defective in TLR4 signaling but also
in the chimeric mice defective in TLR4
signaling that were recipients for bone
marrow transplantation from normal
TLR4-signaling mice. In conclusion, TLR4
in LECs plays an essential role in LPS-
induced inflammatory lymphangiogen-
esis by chemotactic recruitment of macro-
phages. (Blood. 2009;113:2605-2613)
Introduction
Toll-like receptor 4 (TLR4) is a pattern recognition receptor (PRR)
that initiates the innate immune response against Gram-negative
bacteria infection by recognizing lipopolysaccharide (LPS), the
prominent component of the bacteria cell wall.1 The role of TLR4
and its signaling pathway has been extensively studied in macro-
phages, as these cells abundantly express TLR4 and are crucial
players in LPS-induced immune responses.2,3 In response to
infection by Gram-negative bacteria, resident macrophages recog-
nize LPS via surface TLR4,1 process the pathogen, migrate to the
regional draining lymph node (DLN), and present the antigen to
T lymphocytes, resulting in induction of the adaptive immune
response.4-6 During this process, TLR4 activates nuclear factor–B
(NF-B), a canonical transcription factor that mediates various
inflammatory responses, which results in the activation of a variety
of proinflammatory genes in macrophages.4,7-9
TLR4 is also expressed in nonimmune cells, including those
that constitute the vascular system.10,11 The lymphatic vessel has a
specialized structure distinct from blood vessels in several aspects.
Lymphatic endothelial cells (LECs), a major cell type in lymphatic
vessels, express specific markers, respond to different growth
factors, and constitute blind-ended loose initial lymphatic capil-
lary.12-15 Moreover, the function of the lymphatic vessel is unique in
that it absorbs macromolecules, transports interstitial fluid, and
orchestrates proper trafficking and recirculation of immune cells to
the regional lymph node, where the adaptive immune response
occurs.16,17 However, despite the demonstrated function of the
lymphatic vessel as a major player in several immune responses,
the details on the expression level, signaling pathway, and precise
role of TLR4 in LECs remain unknown.
De novo lymphangiogenesis occurs mainly by proliferation/
migration of LECs from pre-existing lymphatic vessels.13 Recent
reports18-21 indicate that lymphangiogenesis occurs largely by the
paracrine effect of abundantly infiltrated macrophages, suggesting
a crucial role of macrophages for lymphangiogenesis. However,
little is known about the mechanism by which macrophages are
recruited to the remodeling lymphatic vessel, particularly in the
Gram-negative bacteria-induced inflammatory condition. Although
recent papers have reported the expression of TLR4 in LECs,22,23
the in vivo role of TLR4 in LECs is poorly understood, not only in
the aspect of immune cell transport but also in the aspect of
inflammatory lymphangiogenesis.
In this study, we investigated the role of TLR4 in LECs using
the LPS-induced peritoneal inflammation model that mimics
peritoneal Gram-negative bacteria infection. We compared LPS-
induced lymphangiogenesis between C3H/HeN (HeN, normal
TLR4 signaling) and C3H/HeJ (HeJ, defective TLR4 signaling)
mice.24 To define the role of LECs specific TLR4 during LPS-
induced lymphangiogenesis, we generated chimeric “N/J” (bone
marrow cells [BMCs] of HeJ was replaced with BMCs from HeN)
mice10 and, as a control, “N/N” (BMCs of HeN was replaced with
BMCs from HeN) mice. We also investigated the role of TLR4 in
LECs on macrophage chemotaxis using the in vitro transwell
migration assay and the adoptive cell transfer experiment in vivo.25
Our results indicate that TLR4 in LECs play a key role in
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LPS-induced lymphangiogenesis, mainly by chemotactic recruit-
ment of macrophages to the lymphatic vessels.
Methods
Mice and LPS treatment
Pathogen-free C3H/HeN (HeN, normal TLR4 signaling mice) and C3H/
HeJ (HeJ, mice with a TLR4 gene missense mutation, thus defective in
TLR4 signaling) mice24 were purchased from SLC (Shizuoka, Japan).
TLR4 knockout (KO) mice in C57BL/6 background3 were donated by Dr
Seung-Hyun Han (Seoul National University; originally provided by
S. Akira, Osaka University, Japan). C57BL/6 mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). B-lacZ mice26 were transferred
from the Institute Pasteur (Paris, France) to the KAIST Animal Facility;
these mice harbor a fragment derived from the p105 promoter with
3 functional NF-B responsive sites upstream of the gene encoding
Escherichia coli -galactosidase with a nuclear localization sequence.
Animal care and experimental procedures were performed under approval
of the Animal Care Committees of KAIST. All mice were maintained in a
specific pathogen–free facility and fed a standard normal diet (PMI
LabDiet; Purina Mills, St Louis, MO) ad libitum with free access to water.
Male mice aged 8 to 10 weeks (21-25 g) were used for experiments. For
LPS-induced peritoneal inflammation, the indicated dose of LPS (from
E coli 0111:B4; Sigma-Aldrich, St Louis, MO) in 200 L of phosphate-
buffered saline (PBS) was injected daily into the peritoneal cavity for the
indicated time. As a control, 200 L of PBS was injected in the same
manner. As a positive control, human VEGF-A (10 g/day; R&D Systems,
Minneapolis, MN) in 200 L PBS was injected in the same manner.
Cell culture and LPS treatment
HEK-293A and THP-1 cells were purchased from ATCC (Manassas, VA) and
maintained in Dulbecco modified Eagle medium (DMEM) and RPMI 1640
medium, respectively, with 10% FBS. BECs (primary blood microvascular
endothelial cells derived from human adult dermis) and LECs (primary lym-
phatic microvascular endothelial cell derived from human adult dermis) were
purchased from Cambrex (East Rutherford, NJ) and maintained in endothelial
cell basal medium-2 with growth supplements (EBM-2 MV). Cells cultured
through passage 4 to 6 were used for the in vitro experiments. LPS was diluted
with the appropriate basal culture media containing 2% fetal bovine serum (FBS)
without other supplements and added to the cells, which were preincubated in
serum-deprived media for 8 hours. Mice LECs were isolated from the peritoneal
lymphangioma model according to the previous report,27 and were maintained
and cultured in EBM-2 MV up to passage 3. The purity of mice LEC was
more than 90%, which was verified by double immunofluorescence staining
of Prox-1 and CD31.
TLR4 knock-down by siRNA transfection
LECs (approximately 50% confluence in a 6-well plate) were transfected
with 180 pmol of TLR4-specific siRNA (Santa Cruz Biotechnology, Santa
Cruz, CA), 180 pmol of nonspecific scramble (sc) RNA (Santa Cruz
Biotechnology), or control dilution buffer using X-tremeGene siRNA
transfection reagent (Roche Applied Science, Indianapolis, IN). After
48 hours of transfection, cells were used for experiments as indicated.
MACS and RT-PCR
For enrichment of CD11b cells infiltrated into diaphragms, the dia-
phragms were incubated with collagenase type II (Sigma-Aldrich) for
1 hour at 37°C, and the collected single cells were incubated in the Blood
Cell lysing buffer (Sigma-Aldrich) for 10 minutes. After several washes in
cold PBS, CD11b cells were enriched using anti-mouse CD11b antibody-
coupled MicroBeads (Miltenyi Biotec, Auburn, CA) and a magnetic-
activated cell sorter (MACS; Miltenyi Biotec) according to the manufactur-
er’s instructions. For reverse transcriptase–polymerase chain reaction
(RT-PCR), total RNA from each sample was extracted using the Total RNA
Isolation System (Promega, Madison, WI) according to the manufacturer’s
instructions. Each cDNA was generated with the Reverse Transcription
System (Promega), and semi-quantitative and quantitative PCR were
performed using Taq DNA polymerase (Bioneer, Daejon, Korea) and iQTM
SYBR Green Supermix (Bio-Rad, Hercules, CA) with the appropriate
primers (Table S1, available on the Blood website; see the Supplemental
Materials link at the top of the online article). Gene expression was
normalized against levels of human or mouse GAPDH.
Immunostaining and morphometric analysis
Immunostaining, morphometric analysis, and flow cytometric analysis were
performed as described in Document S1.
Flow cytometric analysis
PE-conjugated anti–human TLR4 (eBioscience, San Diego, CA), PerCP
Cy5.5–conjugated anti–mouse CD11b, FITC-conjugated anti–mouse CD11b,
PerCP Cy5.5 conjugated anti–mouse F4/80, PE-conjugated anti–mouse
CD11c (all from BD Pharmingen, San Diego, CA) antibodies and FITC-
LPS (Sigma-Aldrich) were used for flow cytometric analysis. For surface
staining, cells were incubated with antibody without permeabilization. For
intracellular staining, cells were treated with BD FACS Permeabilizing
Solution 2 (BD Pharmingen) before incubation with the antibody. The BD
FACSCalibur machine (BD Pharmingen) and FlowJo software (TreeStar,
Ashland, OR) were used for signal uptake and data analysis.
Immunoblotting and ELISA
Mouse anti-human phospho–IB- antibody, rabbit anti–human IB-
antibody (Cell Signaling Technology, Danvers, MA), anti–human -actin
antibody (Sigma-Aldrich) were used for immunoblotting. Quantikine
enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minne-
apolis, MN) were used to measure human CCL2 (MCP-1) and human
CCL5 (RANTES) according to the manufacturer’s protocol.
Chemotactic migration assay
THP-1 monocyte cells (1  106) resuspended in 0.4 mL of serum-free
endothelial cell basal media (EBM) were seeded in the Hanging Cell
Culture Inserts (pore size 5 m; Millipore, Billerica, MA). A total of 1 mL
of culture supernatant from LECs stimulated with the indicated dose of LPS
for 48 hours or from LECs stimulated with 500 ng/mL of LPS for 48 hours
in the presence of TLR4 siRNA (180 pM), scRNA (180 pM), or control
dilution buffer was added into the space between the hanging insert and
each well of a 12-well plate. After 6 hours, the number of cells that
transmigrated outside of the hanging inserts toward the culture supernatant
from LECs were counted with the BD FACSCalibur machine. Migration
was determined as a percentage based on the number of transmigrated cells
per the initially seeded cells.
Adoptive cell transfer and macrophage depletion
To harvest peritoneal macrophages, 1 mL of 3% thioglycollate was injected
intraperitoneally into HeN mice. After 3 days of injections, the peritoneal
macrophages were collected by peritoneal washing with PBS. After red
blood cell (RBC) lysis, the cells were tagged with CFSE green dye
(Molecular Probes [now Invitrogen; Carlsbad, CA]) and counted. CFSE
tagged cells (2  107) were injected into the peritoneal cavity of HeN and
HeJ mice pretreated with intraperitoneal injection of LPS (0.5 mg/kg). For
depletion of endogenous macrophages, mice were either treated with
intraperitoneal injections of clodronate liposome (CDL; 50 mg/kg; a kind
gift from Dr Reto A. Schwendener, University of Zurich, Switzerland) as
previously described28 3 days prior to the adoptive transfer experiment or
treated with CDL (25 mg/kg) every 3 days from the beginning of 7 days of
LPS (0.5 mg/kg per day) injection experiment. Empty control liposome
(CL) was injected as a control.
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Generation of N/N, N/J, J/N and J/J chimeric mice by bone
marrow transplantation
Bone marrow cells were harvested from the femurs and tibias of HeN or
HeJ mice by flushing with ice-cold Dulbecco PBS (Sigma-Aldrich). The
recipient mice (8-week-old HeN and HeJ) were lethally irradiated twice
(5 Gy) with a 3-hour interval using a gamma irradiator (Gammacell 3000;
MDS Nordion, Ottawa, ON). After irradiation, approximately 8  106 bone
marrow cells derived from the HeN or HeJ mice were injected intrave-
nously into HeN and HeJ mice to generate N/N, N/J, J/N and J/J chimeric
mice. The mice were bred in microisolator cages for 2 months prior to the
experiments.
Statistics
Values are presented as means plus or minus standard deviation (SD).
Significant differences between the means were determined by analysis of
variance followed by the Student-Newman-Keuls test. Statistical signifi-
cance was set at P values less than .05.
Results
TLR4 signaling is essential for LPS-induced
lymphangiogenesis and CD11b macrophage infiltration in the
peritoneal side of diaphragm
To assess the function of TLR4 signaling on lymphatic vessels, we
compared LPS-induced inflammatory lymphangiogenesis in mice
with normal (C3H/HeN) and defective (C3H/HeJ) TLR4 signal-
ing.24 Daily intraperitoneal injections of LPS for 7 days induced
robust and dose-dependent increases of lymphatic vessel density in
the peritoneal side of diaphragmatic muscle of HeN mice (Figure
1A,B). To investigate whether the increased lymphatic density
resulted from proliferation of LECs, we examined the number of
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and
PH3 (a nuclear protein of dividing cells) double-positive LECs.
A greater number of LYVE-1/PH3 LECs were observed in the
enlarged lymphatic vessels of mice treated with LPS for 7 days
(Figure S1). Moreover, this LPS-induced lymphangiogenesis was
characterized by an increased number of lymphatic capillary
branching (Figure 1C). These findings indicate that the LPS-
induced increased lymphatic densities mainly resulted from LEC
proliferation and active branching process, which are major cellular
processes of lymphangiogenesis.13,16,19,29 In contrast, no notable
changes in the density and structure of the lymphatic vessels in HeJ
mice in response to LPS-induced inflammation were observed
(Figure 1A). In comparison, daily intraperitoneal injections of
VEGF-A (10 g/day) for 7 days increased lymphatic densities and
the amount of lymphatic capillary branching in both HeN and HeJ
mice without any significant differences (Figure S2), indicating
induction of lymphangiogenesis in response to lymphangiogenic
growth factor is indistinguishable between the HeN and HeJ mice.
Because CD11b macrophages are closely involved in inflamma-
tory lymphangiogenesis,20,30,31 we examined the extent of CD11b
macrophage infiltration in the same region. A marked infiltration of
CD11b macrophages was detected adjacent to the diaphragmatic
lymphatic vessels in HeN mice, whereas only a few CD11b
macrophages were detected in HeJ mice (Figure 1D). Flow
cytometric analysis revealed that CD11b/F4/80 macrophages
that infiltrated into the diaphragm constituted 1.44% of the total
number of cells in the diaphragm of HeN mice compared with
0.35% in HeJ mice (Figure 1E). TLR4 KO mice (C57BL/6
background)3 showed similar largely attenuated responses in
LPS-induced lymphangiogenesis and CD11b macrophage infiltra-
tion in the peritoneal side of the diaphragm (data not shown). These
data indicate that TLR4 signaling is essential for LPS-induced
lymphangiogenesis and adjacent CD11b macrophage infiltration
to the lymphatic vessels in the peritoneal side of the diaphragm.
Profound expression but intracellular localization of TLR4 in
the primary cultured LECs
These findings led us to assess the expression and localization of
TLR4 in primary cultured human LECs from the adult dermis.
Similar to primary cultured BECs from the adult dermis, LEC
exhibited a typical cobblestone appearance (Figure S3A). LECs
expressed not only endothelial cell marker CD31, but also LEC-
specific and distinct markers such as LYVE-1, podoplanin, and
Prox-1 (Figure S3B). Semiquantitative and quantitative RT-PCR
analysis revealed that the expression level of TLR4 mRNA in LECs
was 2.8- and 4.2-fold higher than in THP-1 cells (THP) from a
human monocyte cell line and BECs, respectively; HEK-293A
Figure 1. Comparison of LPS-induced lymphangiogenesis in HeN and HeJ mice
and CD11b macrophage infiltration in the peritoneal side of diaphragm.
(A) HeN and HeJ mice were treated intraperitoneally with the indicated doses of LPS
for 7 days, and diaphragms were immunostained for LYVE-1 (brown) and visualized
with DAB. Representative images of LYVE-1 lymphatic vessels and lymphatic
branching (black arrows) in the peritoneal side of diaphragm muscle. Right panels are
higher magnifications of the black dotted rectangle and show lymphatic branching
(n  4). Scale bars indicate 300 m. (B-E) HeN and HeJ mice were treated with LPS
(0.5 mg/kg/day) intraperitoneally for 7 days. (B,C) Densities of LYVE-1 diaphrag-
matic lymphatic vessels were measured in each given area (3.64 mm2); values were
presented as a percentage per each area (n  4). Numbers of LYVE-1 lymphatic
branching exceeding 50 m in a given area (1 mm2) were counted and presented as
the actual number per field (n  4). Bars represent means plus or minus SD. *P 	 .05
versus HeN. (D) Diaphragms were double immunostained for LYVE-1 (green) and
CD11b (red) and visualized with fluorescent dyes. Note the robust infiltration of
CD11b macrophages in the diaphragmatic lymphatic vessels of HeN but not in HeJ
mice (n  3). Scale bars indicate 200 m. (E) Whole diaphragms were harvested
from HeN and HeJ mice, digested into single cells, and analyzed by flow cytometry.
The number of CD11b/F4/80 macrophages that infiltrated into the diaphragm was
presented as a percentage of the total cell number in the whole diaphragm. Data are
presented as means plus or minus SD. Information on immunostaining and
morphometric analysis is available in Document S1.
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cells (HEK) from a human fibroblast cell line showed no
detectable range of TLR4 expression (Figure 2A). Immunofluo-
rescent analysis revealed that TLR4 was abundant and mainly
localized as granules in the intracellular area in LECs (Figure
2B). In BECs, a lesser amount of TLR4 was mainly localized in
the intracellular-perinuclear area as granules, whereas TLR4
localized as granules largely at the cell surface in THP (Figure
2B), consistent with a previous report.11 No detectable TLR4
signal was found in HEK. To further define the localization of
TLR4 in LECs, flow cytometric analysis was next performed.
THP showed both surface and intracellular TLR4 expression,
whereas most TLR4 was detected in the intracellular compart-
ment in LECs and BECs (Figure 2C). In addition, LECs
incubated with FITC-LPS generated a positive signal for
binding, while no binding was observed with HEK (Figure 2D),
suggesting that LECs have a functional binding receptor for
LPS, such as TLR4. Together, these suggest that LECs express a
high amount of TLR4, mainly in the intracellular area, and that
this TLR4 may function as an internal receptor for LPS.
TLR4 in LECs is a functional receptor mediating LPS-induced
NF-B signaling
As NF-B signaling is one of the major pathways that convey
LPS-TLR4–mediated inflammation in macrophages,32 the interac-
tions among LPS, TLR4, and NF-B signaling were examined in
primary cultured LECs. LPS treatment produced a marked in-
tranuclear translocation of p65, a subunit of NF-B (Figure 3A),
and a substantial increase in phosphorylation of the NF-B
inhibitor, IB-, in a time-dependent manner (Figure 3B). Intrigu-
ingly, upon LPS stimulation, approximately 93% of LECs exhib-
ited nuclear localization of p65, whereas just approximately 41% of
BECs did (Figure 3C,D), indicating that activation of NF-B
signaling in response to LPS is more sensitive in LECs than BECs.
To determine whether LPS-induced NF-B signaling activation is
mediated through TLR4 in LECs, we used TLR4-specific siRNA
(siTLR4) to knock down TLR4 in LECs (Figure 3E). Upon LPS
stimulation, approximately 25% of siTLR4-transfected LECs exhib-
ited nuclear localization of p65, whereas approximately 90% of
Figure 2. Elevated expression but intracellular localization of TLR4
in the primary cultured LECs. (A) Semiquantitative (top panel) and
quantitative (bottom panel) RT-PCR analysis of TLR4 mRNA in cultured
HEK-293A (HEK), THP-1 (THP), BECs, and LECs. Quantitative RT-PCR
analysis is presented in arbitrary units (AU) after normalization to
GAPDH, with THP set as 1. Bars represent means plus or minus SD
(n  3). *P 	 .05 versus THP. (B) Immunostainings of TLR4, CD45, or
CD31, and DAPI nuclear staining in HEK, THP, BECs, and LECs. Scale
bars indicate 10 m. (C) Flow cytometric analysis of the distribution of
TLR4 before permeabilization (top panel) and after permeabilization
(bottom panel). (D) Flow cytometric analysis of the distribution of
FITC-LPS in HEK and LECs. Independent flow cytometric analyses
(n  3-4) show similar findings.
Figure 3. TLR4 in LECs is a functional receptor mediating LPS-
induced NF-B signaling. (A) p65 immunostaining (a subunit of NF-B;
green) in LECs in the absence (LPS
) and presence (LPS) of LPS
stimulation (50 ng/mL for 30 minutes). Scale bars indicate 10 m.
(B) Immunoblotting analysis for phosphorylated IB-, IB-, and -actin
proteins in LECs after LPS (50 ng/mL) stimulation for indicated times.
(C,D) p65 immunostaining in BECs and LECs after LPS stimulation
(500 ng/mL for 60 minutes). Scale bars indicate 100 m. (D) Cells
positive for p65 intranuclear staining were counted; the values are
presented as a percentage of the total cell number. Bars represent mean
plus or minus SD (n  4). *P 	 .05 versus BECs. (E) TLR4 knock-down
by siTLR4 (siT4) but not scTLR4 (scT4) was confirmed by semiquantita-
tive RT-PCR in LECs. (F,G) LECs were transfected with C (control
transfection), scT4, and siT4, stimulated with LPS (500 ng/mL for
60 minutes), and immunostained for p65. Scale bars indicate 100 m.
Cells positive for p65 intranuclear staining were counted and presented
as a percentage of total cell number. Bars represent means plus or minus
SD (n  4). *P 	 .05 versus LPS
; #P 	 .05 versus scT4 plus LPS.
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control-transfected and approximately 86% of scTLR4 (nonspe-
cific scrambled siRNA)–transfected LECs exhibited nuclear local-
ization of p65 (Figure 3F,G), indicating that TLR4 is essential for
LPS-induced NF-B signaling activation in LECs. We also ana-
lyzed the activity of NF-B in vivo using a reporter mouse
expressing lacZ under control of the p105 promoter, which contains
3 NF-B responsive elements.26 Upon NF-B activation in these
mice, one of the NF-B subunits, p65, translocates to the nucleus
and binds the p105 promoter, which induces lacZ expression.
Consistent with a previous report,33 NF-B was predominantly
expressed in LYVE-1 lymphatic capillaries, but not in the blood
vessel of the diaphragm (Figure S4 top panel). Moreover, the
LPS-induced, newly developed branching lymphatic vessels also
expressed NF-B (Figure S4 bottom panel). These data suggest
that TLR4-NF-B signaling in LECs could be a crucial pathway
that conveys LPS-induced inflammation and lymphangiogenesis
both in vitro and in vivo.
LPS-TLR4 signaling in LECs does not directly promote cell
proliferation/migration, tube formation, and expression of
lymphangiogenic molecules
To examine whether LPS had any direct effect on lymphangiogen-
esis, primary cultured human LECs were stimulated with several
concentrations of LPS. However, none of the concentrations
examined (50, 500, and 5000 ng/mL) significantly promoted LEC
proliferation/migration (Figure S5A,B) or tube formation (Figure
S5C,D), whereas the media containing 10% serum with growth
supplements markedly induced LEC proliferation/migration and
tube formation. To assess whether LPS induces the expression of
lymphangiogenic growth factors, such as VEGF-C and VEGF-D,
and their receptors, VEGFR2 and VEGFR3, quantitative RT-PCR
was performed. No significant change in expression of VEGF-C,
VEGF-D, VEGFR3, and VEGFR2 in response to LPS (5-50 000 ng/
mL) was detected (Figure S5E). Thus, LPS could not directly
induce lymphangiogenesis in a cell-autonomous manner.
TLR4 in LECs mediates LPS-induced chemokine up-regulation
and macrophage chemotaxis
Because LPS-induced lymphangiogenesis is accompanied with CD11b
macrophage infiltration in a TLR4-dependent manner, we next deter-
mined whether primary cultured human LECs produce chemokines for
macrophages in a TLR4-dependent manner. LPS markedly increased
the mRNA expressions of major chemokines for macrophage, such as
CCL2, CCL5, and CX3CL1,34-40 in time- and dose-dependent manners
(Figure 4A,B). Treatment with LPS (500-50 000 ng/mL for 4 hours)
induced CCL2 by approximately 20- to 40-fold, CCL5 by approxi-
mately 30- to 110-fold, and CX3CL1 by approximately 47- to 76-fold
(Figure 4A,B). The LPS-induced increase of CCL2, CCL5, and
CX3CL1 in human LECs were largely dependent on TLR4, as shown
by the significant reduction in gene levels in human LECs treated with
Figure 4. TLR4 mediates LPS-induced chemokine up-regulation and
monocytes chemotaxis in LECs. LECs were stimulated with LPS
(500 ng/mL) for indicated times (A), 4 hours (C), or 48 hours (E,H), or
stimulated with indicated amounts of LPS for 4 hours (B) or 48 hours
(D,G). Prior to LPS stimulation, LECs were transfected with control (C),
scTLR4 (scT4), or siTLR4 (siT4) (C,E,H). (A-C) The CCL2, CCL5, and
CX3CL1 mRNA levels were analyzed by quantitative RT-PCR. The mRNA
level of each gene were normalized to GAPDH and presented as a fold
increase compared with the control. (D,E) CCL2 and CCL5 protein levels
in the LEC culture supernatant were measured by ELISA. (F) Schematic
diagram of the monocyte chemotactic migration assay. (G,H) The number
of THP-1 monocytes that migrated from the hanging transwell to the
culture supernatants of the LPS-stimulated LECs in the bottom were
counted and presented as a percentage of the number of initially seeded
cells. Bars represent mean plus or minus SD (n  4). *P 	 .05 versus
LPS
; #P 	 .05 versus scT4 LPS.
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siTLR4 compared with scTLR4 (Figure 4C). The basal expres-
sion level of these chemokines in human LECs were not
markedly altered by either siTLR4 or scTLR4 treatment. ELISA
assays revealed that LPS increased CCL2 and CCL5 protein
levels in the culture media of human LECs in dose-dependent
and TLR4-dependent manners (Figure 4D,E). Notably, LPS
treatment (5000 ng/mL) increased the level of CCL2 protein
from approximately 29 ng/mL up to approximately 780 ng/mL
for 48 hours. Consistent with these findings, LPS treatment
(500 ng/mL for 4 hours) increased the level of CCL2 mRNA
(HeN vs HeJ, 118.9-fold vs 2.6-fold; P 	 .05), CCL5 (HeN vs
HeJ, 1023.9-fold vs 3.3-fold; P 	 .05), and CX3CL1 (HeN vs
HeJ, 2.5-fold vs 1.1-fold; P 	 .05) mRNA in the primary
cultured mice LECs derived from HeN and HeJ (Figure S6B).
Moreover, expression of CCL2 was markedly up-regulated in
the diaphragmatic lymphatic vessels by LPS treatment in HeN
mice, whereas it was not changed in the diaphragmatic lym-
phatic vessels by LPS treatment in HeJ mice (Figure S6C). We
further determined the chemotactic activity of the secreted
chemokines from LPS-stimulated LECs using a transwell migra-
tion assay (Figure 4F). The media supernatant from LECs
stimulated with different concentrations of LPS (0-5000 ng/mL)
for 48 hours increased the chemotactic migration of THP-1
monocytes in a dose-dependent manner (Figure 4G). Notably,
the chemotactic migration of monocytes was reduced when
monocytes were incubated with media supernatant from siTLR4-
transfected LECs compared with control- or scTLR4-transfected
LECs with LPS stimulation (Figure 4H). These data indicate
that TLR4 signaling in LECs is critical for LPS-induced
up-regulation of chemokines for trafficking and chemotactic
migration of macrophages.
TLR4 signaling in LECs contributes to macrophage recruitment
and infiltration to draining lymphatic vessels in vivo
To investigate whether TLR4 signaling in LECs contributes to macro-
phage chemotaxis in vivo, we performed an adoptive cell transfer
experiment25 by intraperitoneal transfer of CFSE green dye–tagged
peritoneal macrophages from HeN mice into the peritoneal cavity of
HeN and HeJ mice (Figure S7A). Flow cytometric analysis revealed that
approximately 80% to 85% of the inflammatory cells collected from
HeN mice with thioglycollate-induced peritonitis were CD11b/F4/80
macrophages (Figure S7B). Confocal images of the diaphragms re-
vealed higher numbers of the transferred cells along the diaphragmatic
lymphatic vessels in HeN mice compared with HeJ mice at 4 hours
(1.75-fold) and 24 hours (3.18-fold) following the intraperitoneal
injection of LPS (Figure 5A,B). The transferred cells were mainly
located in the diaphragmatic lymphatic vessel, but not in the lymphatic
vessels of peritoneal cavity sites, such as mesentery or abdominal wall
(data not shown). To exclude the effect of endogenous macrophages on
recruitment and infiltration of the transferred macrophages to the
draining lymphatic vessel, we first depleted endogenous macrophages
by intraperitoneal injection of clodronate liposome (CLD)28 and then
performed the adoptive cell transfer experiment. Even after CLD
treatment, the recruitment of macrophages to draining lymphatic vessel
in HeN mice was higher (approximately 1.8-fold) compared with HeJ
mice. Similar differences in the extent of recruitment and infiltration of
macrophages between HeN and HeJ mice were observed in the
treatment of PBS and CL (Figure 5C). Thus, LPS-TLR4 signaling in
LECs substantially contributes to chemotaxis for the recruitment and
infiltration of macrophages to the draining lymphatic vessel, which
could be mediated mainly through the secretion of various chemokines
from the LECs. Z-stack analysis of confocal images in the lymphatic
vessels was performed to further define the location of these transferred
macrophages. Horizontal and vertical sections of Z-stack images
showed that all transferred cells were inside the lumen of the lymphatic
capillary in HeN mice (Figure S8). These data indicate that the
transferred cells might be drained into the initial lymphatic capillary and
were in the process of transmigration to the DLN.
TLR4 in LECs is a prime initiator in the LPS-induced
lymphangiogenesis by macrophage recruitment
To define the role of LEC-specific TLR4 in LPS-induced diaphragmatic
lymphangiogenesis in the context of interaction with macrophage, equal
numbers of BMCs from HeN mice were transplanted to lethally
irradiated HeN and HeJ mice (referred to as N/N and N/J mice,
respectively), and equal numbers of BMCs from HeJ mice were
Figure 5. TLR4 signaling contributes to macrophage trafficking to
the draining lymphatic vessels. The diaphragms were analyzed at
4 and 24 hours after intraperitoneal injection of LPS (0.5 mg/kg) and
transfer of approximately 2  107 of CFSE-tagged peritoneal macro-
phages (green) into the peritoneal cavity. (A) Whole diaphragms were
harvested and then immunostained with LYVE-1; LYVE-1 diaphragmatic
lymphatic vessels (red) and injected cells (green) were visualized. Scale
bars indicate 200 m. (B) The number of transferred cells (green) along
the lymphatic vessel (red) was divided by the total area of LYVE-1
lymphatic vessel in a given area (1 mm2). (C) At 3 days after intraperito-
neal injection of PBS, CL (50 mg/kg), or CDL (50 mg/kg) into HeN and
HeJ mice, LPS (0.5 mg/kg) and approximately 2  107 of CFSE-tagged
peritoneal macrophages were injected intraperitoneally. After 4 hours,
whole diaphragms were harvested. The number of transferred cells along
the lymphatic vessel was divided by the total area of the LYVE-1
lymphatic vessel in a given area (1 mm2). The values are presented as
arbitrary units (AU) compared with the value from HeN mice as 1. Bars
represent means plus or minus SD (n  4). *P 	 .05 versus HeN.
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transplanted to lethally irradiated HeN and HeJ mice (referred to as J/N
and J/J mice, respectively). After 2 months, the N/N, N/J, J/N, and J/J
mice were intraperitoneally treated with LPS for 7 days. Similar to the
effect of LPS in HeN mice, LPS profoundly increased lymphatic
densities and branching in the peritoneal side of the diaphragm in N/N
mice (Figure 6A-D). In contrast, these phenomena were largely attenu-
ated or absent in N/J, J/N, and J/J mice, indicating that TLR4 in both
LECs and macrophages have an interactive role in LPS-induced
lymphangiogenesis (Figure 6A-D). To clarify this interactive role in the
LPS-induced lymphangiogenesis, we first evaluated the contribution of
LEC-specific LPS-TLR4 signaling on the extent of CD11b macro-
phage infiltration into the lymphatic vessels. Similar to the effect of LPS
in HeN mice, LPS markedly increased CD11b macrophage infiltration
adjacent to the lymphatic vessels in N/N and J/N mice, but had little
effect in N/J and J/J mice, indicating that LEC-specific TLR4 contrib-
utes to macrophage infiltration by secretion of chemokines regardless of
the presence or absence of TLR4 in macrophages (Figure 6D). Second,
to evaluate the role of macrophages in LPS-induced lymphangiogenesis,
we depleted macrophages by CDL treatment during LPS stimulation in
the HeN mice. Treatment of CDL but not CL largely abolished the
LPS-induced increase of lymphatic densities and branching in the
peritoneal side of diaphragm (Figure S9), indicating that the infiltrated
macrophages play an important role in LPS-induced lymphangiogen-
esis. Finally, to elucidate the exact mechanism of lymphangiogenesis by
the infiltrating CD11b macrophages, we analyzed VEGF-C and
VEGF-D mRNAlevels in the CD11bmacrophages that infiltrated into
the diaphragm of HeN and HeJ mice after LPS stimulation. The
CD11b cells from HeN mice expressed higher levels of VEGF-C
(approximately 7.5-fold) and VEGF-D (approximately 2.0-fold) than
those from HeJ mice (Figure 6E). This suggests that the infiltrating
CD11b macrophages by LPS-TLR4 signaling in LECs could be the
major source for lymphangiogenic growth factors. Furthermore, the lack
of lymphangiogenesis in the J/N mice again suggests that activated
TLR4 in LECs is a prime initiator for the macrophage recruitment,
whereas activated TLR4 in macrophages is a secondary critical compo-
nent for the LPS-induced lymphangiogenesis through enhanced produc-
tion of lymphangiogenic growth factors. Taken together, our data
indicate that TLR4 in LECs is a critical initiator of LPS-induced
lymphangiogenesis by chemotactic recruitment of activated macro-
phages, which are the major source for lymphangiogenic growth factors.
Discussion
Here, we found that TLR4 in LECs plays a key role in LPS-induced
inflammatory lymphangiogenesis by enhancing the recruitment
and infiltration of macrophages around lymphatic vessels. LECs
actively participate in these processes by producing major chemo-
kines through the LPS-TLR4-NF-B signaling pathway, and the
macrophages recruited to the lymphatic vessels by chemotactic
stimuli from LECs act as the major source of lymphangiogenic
growth factors, including VEGF-C and VEGF-D (Figure 7). Taken
together, our findings not only clarify the mechanism of the role of
TLR4 in LEC involvement in LPS-induced inflammatory lym-
phangiogenesis, but also highlight close functional interactions
between LECs and macrophages in these processes.
We observed profound changes in the lymphatic vessels in
response to LPS stimulation in HeN mice with normal TLR4
signaling, whereas almost no changes were observed in in HeJ
mice with defective TLR4 signaling. This striking difference led us
to explore the role of TLR4 in LECs in LPS-induced inflammatory
lymphangiogenesis at in vitro and in vivo levels. Intriguingly, a
significant amount of TLR4 was expressed in the intracellular area
of LECs and LPS was able to bind to the intracellular TLR4, even
though the functional implication of this subcellular localization
warrants future investigation. Furthermore, LPS-TLR4-NF-B
signaling was approximately 2-fold more sensitive in LECs than in
BECs, and the NF-B signal was constitutively active in the
diaphragmatic lymphatic vessels but not blood vessels in B-lacZ
mice. This constitutive and active NF-B signaling in the lym-
phatic vessels might be the result of high expression and activation
of TLR4 and other PRRs by various agonists, including various
Gram-negative bacteria, which are the main normal flora of the
peritoneal cavity. These results clearly indicate that the LEC is a
crucial cell type responding sensitively to LPS. Immune cells,
Figure 6. LEC-specific LPS-TLR4 signaling is critical in LPS-induced
lymphangiogenesis. N/N, N/J, J/N, and J/J mice were treated with
intraperitoneal injection of LPS (0.5 mg/kg per day) for 7 days; the
diaphragms were then harvested, whole-mounted, and immunostained for
LYVE-1 (brown; scale bars indicate 300 m) (A) or coimmunostained
for LYVE-1 (green) and CD11b (red) (D). Scale bars indicate 200 m.
(A,D) Note that the LPS-induced increase of lymphatic densities and
branchings and infiltration of CD11b cells adjacent to lymphatic vessels
of the diaphragm in N/N mice are largely abrogated in N/J mice.
(B,C) Densities of the LYVE-1 diaphragmatic lymphatic vessels were
measured in each given area (3.64 mm2), and the values are presented as
the percentage of total area of the field. The number of LYVE-1 lymphatic
branching exceeding 50 m in length in each given area (1 mm2) was
counted, and the absolute numbers are presented. Bars represent means
plus or minus SD (n  4). *P 	 .05 versus N/N. (E) The CD11b cells in
the diaphragm of HeN and HeJ mice after LPS stimulation (0.5 mg/kg per
day) for 5 days were collected and enriched by MACS. The VEGF-C and
VEGF-D mRNA levels in CD11b cells were analyzed by quantitative
RT-PCR. mRNA levels for each gene were normalized to GAPDH, and the
values are presented in arbitrary units (AU) compared with the value from
HeN mice set as 1. Bars represent means plus or minus SD (n  4).
*P 	 .05 versus HeN.
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including monocytes/macrophages, are major cell types that re-
spond to pathogen-induced inflammation and also use TLR4-
NF-B signaling upon LPS stimulation for maturation and mobili-
zation to DLN during the adaptive immune response.4,41 Recently,
growing evidence has shown that nonimmune cells, such as
platelets,42 fibroblasts,43,44 pulmonary epithelial cells,45 and BECs,11
also have functional TLR4, which mediates the production of
various inflammatory mediators by LPS. Based on the high levels
of TLR4 and the sensitive activation of NF-B signaling in LECs
compared with BECs upon LPS stimulation, the lymphatic vessel
may not just be a passive conduit for immune cell transport, but
may also be one of the active players in immune modulation.
Because we also observed marked infiltration of CD11b macro-
phages around the lymphatic vessels by LPS stimulation in HeN mice,
compared with nearly no infiltration in HeJ mice, we hypothesized that
TLR4 in LECs may function as a recruiter of macrophages by secreting
chemokines upon LPS stimulation. Therefore, we analyzed the expres-
sion and production levels of major chemokines for macrophages, such
as CCL2, CCL5, and CX3CL1,34-40 in cultured LECs derived from
human, and HeN and HeJ mice. Interestingly, our data showed that LPS
induced a robust increase in production of the chemokine mRNAs in a
TLR4-dependent manner. In addition, our in vitro transwell migration
assay and in vivo adoptive cell transfer experiment revealed that the
chemotactic migration of macrophages to LECs is largely dependent on
TLR4 signaling in LECs. Macrophages are also known as a major
supplier for the production of chemokines during LPS-induced inflam-
mation.46,47 Therefore, LECs and macrophages may closely interact for
the production of chemokines on the recruitment and infiltration of
immune cells, including macrophages to draining lymphatic vessels
during LPS-induced inflammation (Figure 7).
Our in vitro data in Figure S3 argue against the idea that the
LPS-TLR4 pathway in LECs may directly induce lymphangiogen-
esis in a cell-autonomous manner. Rather, the LPS-TLR4 pathway
in LECs indirectly induces lymphangiogenesis by the production of
major chemotactic factors for macrophages that were able to
secrete lymphangiogenic factors. Our data clearly revealed that
TLR4 in LECs is essential in this scenario, as shown by marked
reductions in LPS-induced chemokine expression and production
in the primary cultured human LECs knocked down for TLR4,
LECs from the HeJ mouse, and lymphatic vessels in the HeJ
mouse. Interestingly, the contribution of lymphatic vessels on
macrophage trafficking also affected the lymphatic vessels, result-
ing in robust lymphangiogenesis by lymphangiogenic growth
factors secreted from the infiltrated macrophages. In support of
this, our data showed that LPS-stimulated peritoneal macrophages
expressed significant amounts of VEGF-C and VEGF-D. More-
over, depletion of macrophages by CLD largely abolished LPS-
induced inflammatory lymphangiogenesis, and J/N mice, which
have defective TLR4 signaling in macrophages, did not develop
LPS-induced lymphangiogenesis even though abundant macro-
phages infiltrated into the diaphragm, strongly indicating that
lymphangiogenic growth factors secreted from the infiltrated
macrophages are the main sources for LPS-induced inflammatory
lymphangiogenesis. This LPS-induced extensive lymphangiogen-
esis may play an important role in draining inflammatory macromol-
ecules, immune cells, and debris from inflamed tissues.
The incidence of fatal Gram-negative bacterial sepsis is increas-
ing in proportion to the growing numbers of immunocompromised
patients.48 Several new drugs are currently being developed to treat
this, including TLR4-blocking agents.49 In the past, TLR4 in
“effector cells” such as macrophages were considered the main
target of these drugs.50 However, as “conduit cells” for immune cell
transport, the active contribution of LECs in LPS-induced inflam-
mation in our study implies that the control and modulation of
TLR4 function in LECs can be a potential and novel alternative
target to overcome Gram-negative bacteria–induced mortality.
In conclusion, TLR4 in LECs is an essential molecule in the
production of major chemokines for macrophages and in the subsequent
recruitment of macrophages to the lymphatic vessel during LPS-induced
lymphangiogenesis. In addition, the macrophages induced to infiltrate
by the LPS-TLR4 pathway in LECs contribute to robust lymphangiogen-
esis (Figure 7). These TLR4-mediated interactions between LECs and
macrophages are central mechanisms in the innate/adaptive immune
response and pathogen clearance.
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Figure 7. Schematic diagram on the role of TLR4 in LECs in the context of
LPS-induced inflammation, resulting in lymphangiogenesis by chemotactic
migration of macrophages that produce VEGF-C and VEGF-D. The LEC actively
responds to LPS with intracellular TLR4 by secreting various chemokines, such as
CCL2, CCL5, and CX3CL1. Here, NF-B may contribute to the signaling pathway.
The migrated and recruited macrophages, in turn, produce lymphangiogenic factors,
such as VEGF-C and -D, resulting in robust lymphangiogenesis. Therefore, an active
crosstalk connects LECs and macrophages in the context of LPS-induced inflamma-
tion, the process of which is under the control of TLR4 in LECs.
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